Literature DB >> 22201039

Role of secondary mediators in caffeine-mediated neuroprotection in maneb- and paraquat-induced Parkinson's disease phenotype in the mouse.

Sharawan Yadav1, Satya Prakash Gupta, Garima Srivastava, Pramod Kumar Srivastava, Mahendra Pratap Singh.   

Abstract

Maneb and paraquat are known to induce Parkinson's disease (PD) phenotype, however, caffeine offers neuroprotection. Nitric oxide (NO) acts an important mediator in PD phenotype and tyrosine kinase (TK), nuclear factor kappa B (NF-kB), p38 mitogen activated protein kinase (p38 MAPK) are known to regulate its production. The present study aimed to elucidate the role of caffeine in the regulation of NO production and microglial activation and their subsequent contribution in dopaminergic neuroprotection. The animals were treated with caffeine and/or maneb and paraquat along with controls. In a few sets of experiments, the animals were also treated with aminoguanidine, an inhibitor of inducible NO synthase, pyrrolidine dithiocarbamate (PDTC), an inhibitor of NF-kB, genistein, an inhibitor of TK or SB202190, an inhibitor of p38 MAPK. Tyrosine hydroxylase (TH)-immunoreactivity and anti-integrin αM (OX-42) staining were performed to assess the number of dopaminergic neurons and activation of microglia, respectively. NO was measured in terms of nitrite, however, the expressions of p38 MAPK, interleukin (IL)-1β, NF-kB and TK were checked by western blot analyses. Maneb and paraquat induced the number of degenerating dopaminergic neurons, microglial cells, nitrite content, expressions of IL-1β, p38 MAPK, NF-kB and TK and caffeine co-treatment reduced the level of such alterations. Reductions were more pronounced in the animals co-treated with aminoguanidine, PDTC, genistein or SB202190. The results obtained thus demonstrate that caffeine down-regulates NO production, neuroinflammation and microglial activation, which possibly contribute to neuroprotection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22201039     DOI: 10.1007/s11064-011-0682-0

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  43 in total

1.  Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia.

Authors:  W G Kim; R P Mohney; B Wilson; G H Jeohn; B Liu; J S Hong
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

Review 2.  Do environmental toxins cause Parkinson's disease? A critical review.

Authors:  C M Tanner; J W Langston
Journal:  Neurology       Date:  1990-10       Impact factor: 9.910

3.  Long term exposure to cypermethrin induces nigrostriatal dopaminergic neurodegeneration in adult rats: postnatal exposure enhances the susceptibility during adulthood.

Authors:  Anand Kumar Singh; Manindra Nath Tiwari; Ghanshyam Upadhyay; Devendra Kumar Patel; Dhirendra Singh; Om Prakash; Mahendra Pratap Singh
Journal:  Neurobiol Aging       Date:  2010-04-03       Impact factor: 4.673

4.  Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats.

Authors:  Francesca Cicchetti; Nicolas Lapointe; Antoine Roberge-Tremblay; Martine Saint-Pierre; Lincoln Jimenez; Brooks W Ficke; Robert E Gross
Journal:  Neurobiol Dis       Date:  2005-11       Impact factor: 5.996

5.  Pathological changes in dendrites of substantia nigra neurons in Parkinson's disease: a Golgi study.

Authors:  S Patt; H J Gertz; L Gerhard; J Cervós-Navarro
Journal:  Histol Histopathol       Date:  1991-07       Impact factor: 2.303

6.  Nigrostriatal proteomics of cypermethrin-induced dopaminergic neurodegeneration: microglial activation-dependent and -independent regulations.

Authors:  Anand Kumar Singh; Manindra Nath Tiwari; Anubhuti Dixit; Ghanshyam Upadhyay; Devendra Kumar Patel; Dhirendra Singh; Om Prakash; Mahendra Pratap Singh
Journal:  Toxicol Sci       Date:  2011-05-10       Impact factor: 4.849

7.  Gene expression profiles of mouse striatum in control and maneb + paraquat-induced Parkinson's disease phenotype: validation of differentially expressed energy metabolizing transcripts.

Authors:  Suman Patel; Kavita Singh; Seema Singh; Mahendra Pratap Singh
Journal:  Mol Biotechnol       Date:  2008-04-02       Impact factor: 2.695

8.  Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells.

Authors:  Kazuhiro Nakaso; Satoru Ito; Kenji Nakashima
Journal:  Neurosci Lett       Date:  2007-12-23       Impact factor: 3.046

9.  Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum.

Authors:  Seema Singh; Kavita Singh; Satya Prakash Gupta; Devendra Kumar Patel; Vinod Kumar Singh; Raj Kumar Singh; Mahendra Pratap Singh
Journal:  Brain Res       Date:  2009-06-09       Impact factor: 3.252

10.  Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease.

Authors:  Henrik Wilms; Philip Rosenstiel; Jobst Sievers; Günther Deuschl; Luigi Zecca; Ralph Lucius
Journal:  FASEB J       Date:  2003-01-21       Impact factor: 5.191

View more
  18 in total

1.  The Therapeutic Implications of Tea Polyphenols Against Dopamine (DA) Neuron Degeneration in Parkinson's Disease (PD).

Authors:  Zhi Dong Zhou; Shao Ping Xie; Wuan Ting Saw; Patrick Ghim Hoe Ho; Hongyan Wang; Zhou Lei; Zhao Yi; Eng King Tan
Journal:  Cells       Date:  2019-08-16       Impact factor: 6.600

2.  Neuroprotective role of Withania somnifera root extract in maneb-paraquat induced mouse model of parkinsonism.

Authors:  Jay Prakash; Satyndra Kumar Yadav; Shikha Chouhan; Surya Pratap Singh
Journal:  Neurochem Res       Date:  2013-02-22       Impact factor: 3.996

Review 3.  Does restraining nitric oxide biosynthesis rescue from toxins-induced parkinsonism and sporadic Parkinson's disease?

Authors:  Satya Prakash Gupta; Sharawan Yadav; Naveen Kumar Singhal; Manindra Nath Tiwari; Sarad Kumar Mishra; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2013-07-31       Impact factor: 5.590

Review 4.  Strategies for Improving Photodynamic Therapy Through Pharmacological Modulation of the Immediate Early Stress Response.

Authors:  Daniel J de Klerk; Mark J de Keijzer; Lionel M Dias; Jordi Heemskerk; Lianne R de Haan; Tony G Kleijn; Leonardo P Franchi; Michal Heger
Journal:  Methods Mol Biol       Date:  2022

5.  Pesticides, microglial NOX2, and Parkinson's disease.

Authors:  Thomas Taetzsch; Michelle L Block
Journal:  J Biochem Mol Toxicol       Date:  2013-01-24       Impact factor: 3.642

6.  Silymarin- and melatonin-mediated changes in the expression of selected genes in pesticides-induced Parkinsonism.

Authors:  Naveen Kumar Singhal; Amit Kumar Chauhan; Swatantra Kumar Jain; Rishi Shanker; Chetna Singh; Mahendra Pratap Singh
Journal:  Mol Cell Biochem       Date:  2013-08-22       Impact factor: 3.396

7.  Chronic caffeine ingestion causes microglia activation, but not proliferation in the healthy brain.

Authors:  Rob Steger; Arifa Kamal; Sara Lutchman; Liliana Intrabartolo; Rabia Sohail; Joshua C Brumberg
Journal:  Brain Res Bull       Date:  2014-05-29       Impact factor: 4.077

8.  Ibuprofen abates cypermethrin-induced expression of pro-inflammatory mediators and mitogen-activated protein kinases and averts the nigrostriatal dopaminergic neurodegeneration.

Authors:  Ashish Singh; Pratibha Tripathi; Om Prakash; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2015-12-12       Impact factor: 5.590

Review 9.  Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review.

Authors:  Marla Rivera-Oliver; Manuel Díaz-Ríos
Journal:  Life Sci       Date:  2014-02-13       Impact factor: 5.037

Review 10.  Nutritional habits, risk, and progression of Parkinson disease.

Authors:  Roberto Erro; Francesco Brigo; Stefano Tamburin; Mauro Zamboni; Angelo Antonini; Michele Tinazzi
Journal:  J Neurol       Date:  2017-10-10       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.